Home > Publications Database > Dermal Alpha‐Synuclein Aggregation in Seed Amplification Assays for Parkinson's Disease Subtype Differentiation > print

001     282536
005     20260105130516.0
024 7 _ |a pmid:41316710
|2 pmid
024 7 _ |a 10.1111/ene.70453
|2 doi
024 7 _ |a 1351-5101
|2 ISSN
024 7 _ |a 1468-1331
|2 ISSN
024 7 _ |a pmc:PMC12662814
|2 pmc
037 _ _ |a DZNE-2025-01299
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Vieregge, Magdalena
|b 0
245 _ _ |a Dermal Alpha‐Synuclein Aggregation in Seed Amplification Assays for Parkinson's Disease Subtype Differentiation
260 _ _ |a Oxford [u.a.]
|c 2025
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1765544527_25188
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Skin biopsies and seed amplification assays (SAA) provide a sensitive and potentially quantitative method to detect alpha-synuclein (a-syn) aggregation in peripheral nerve fibers in Parkinson's disease (PD). Relating to the previously published hypothesis that PD may either originate in the peripheral (body-first) or central (brain-first) nervous system, we investigated whether patients with clinical features that have been reported to be associated with a suspected body-first subtype of PD exhibit higher levels of a-syn aggregation in dermal nerve fibers compared to those without these features. Patients with isolated REM sleep behavior disorder (iRBD) representing a suspected premotor stage of body-first PD were studied in comparison to the PD cohort.Patients were categorized on the basis of clinical features, and SAA parameters such as lag time, number of positive curves, and titers were analyzed and correlated with clinical features.Although patients with clinical features of suspected body-first PD showed slightly higher titers, significant differences were mainly observed between iRBD patients and PD patients.Our data suggest that widespread α-syn aggregation in advanced PD limits the use of SAA in skin biopsies for subtype differentiation.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 7 |a Parkinson's disease
|2 Other
650 _ 7 |a REM sleep behavior disorder
|2 Other
650 _ 7 |a alpha‐synuclein
|2 Other
650 _ 7 |a seeding amplification assay
|2 Other
650 _ 7 |a skin biopsy
|2 Other
650 _ 7 |a alpha-Synuclein
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Parkinson Disease: metabolism
|2 MeSH
650 _ 2 |a Parkinson Disease: diagnosis
|2 MeSH
650 _ 2 |a Parkinson Disease: classification
|2 MeSH
650 _ 2 |a Parkinson Disease: pathology
|2 MeSH
650 _ 2 |a Parkinson Disease: complications
|2 MeSH
650 _ 2 |a alpha-Synuclein: metabolism
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Skin: metabolism
|2 MeSH
650 _ 2 |a Skin: pathology
|2 MeSH
650 _ 2 |a Skin: innervation
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a REM Sleep Behavior Disorder: metabolism
|2 MeSH
700 1 _ |a Kuzkina, Anastasia
|b 1
700 1 _ |a Janzen, Annette
|b 2
700 1 _ |a Oertel, Wolfgang H.
|b 3
700 1 _ |a Sommerauer, Michael
|0 P:(DE-2719)9003277
|b 4
|u dzne
700 1 _ |a Volkmann, Jens
|b 5
700 1 _ |a Doppler, Kathrin
|0 0000-0003-2883-0009
|b 6
773 _ _ |a 10.1111/ene.70453
|g Vol. 32, no. 12, p. e70453
|0 PERI:(DE-600)2020241-6
|n 12
|p e70453
|t European journal of neurology
|v 32
|y 2025
|x 1351-5101
856 4 _ |u https://pub.dzne.de/record/282536/files/DZNE-2025-01299.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/282536/files/DZNE-2025-01299.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:282536
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9003277
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-12
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-12
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J NEUROL : 2022
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-12
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-12
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J NEUROL : 2022
|d 2024-12-12
920 1 _ |0 I:(DE-2719)1013020
|k AG Petzold
|l Vascular Neurology
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1013020
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21